Clinical Trials Logo
  1. Home
  2. Type 1 Diabetes
  3. NCT04909983
  4. Details
NCT04909983 Clinical Trial

An Explorative Study of Treatment of Contact Dermatitis Due to DiabetesDevices

Type 1 Diabetes Clinical Trial

Official title:
A Single Center Explorative Study of the Treamtent ofDiabetes Patients With Contact Dermatitits Caused byInsulin Infusion Pump or Glucose Monitor

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT04909983
Other study ID # DPLX-PT01
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date May 19, 2021
Est. completion date October 1, 2022

Study information
Verified date November 2022
Source Copenhagen University Hospital at Herlev
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A feasibility study of treatment with a occlusive medical device or patch in pediatric patients with type 1 diabetes suffering from irritative contact dermatitis due to diabetes devices.

Recruitment information / eligibility
Status Terminated
Enrollment 17
Est. completion date October 1, 2022
Est. primary completion date October 1, 2022
Accepts healthy volunteers No
Gender All
Age group 6 Years to 20 Years
Eligibility Inclusion Criteria: - Signed informed consent, and for patients under the legal age consent by a legal guardian - Clinically confirmed, active and evaluable irritant contact dermatitis (ICD) - Age 6-20 at the time of signing the informed consent form (ICF) - Ability to answer study questionnaires Exclusion Criteria: - Any type of skin irritation other than ICD - Use of occlusive therapy for the treatment of their ICD, or unwilling to refrain from this treatment for duration of study - For any other reason considered unsuitable by the investigator - Pregnant or of child-bearing potential unwilling to use acceptable effective contraception

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• DPLX-PT1
A polymer skin patch for occlusional therapy
Other:
• Control arm
Standard of care

Locations
Country Name City State
Denmark Pediatric Department, Herlev Hospital Herlev

Sponsors (1)
Lead Sponsor Collaborator
Copenhagen University Hospital at Herlev

Country where clinical trial is conducted

Denmark, 

Outcome
Type Measure Description Time frame Safety issue
Primary Response rate of active treatment versus standard of care 8 days after active treatment compared to 8 days after standard of care
Secondary Time to resolution of Irritative contact dermatitis After 8 days
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Recruiting NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Phase 4
Completed NCT02855307 - Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes Phase 2